Inhibition of ATF2 activity to treat cancer

Details Inhibition of ATF2 activity to treat cancer Inhibition of ATF2 activity to treat cancer

2011-05-03

2011-05-03

Rawlings, Stephen L (Department: 1643)

Chemistry: molecular biology and microbiology

Vector, per se

C536S023500, C530S300000, C530S324000, C530S350000

Reexamination Certificate

active

07935525

ABSTRACT:
The present invention relates to novel therapies for cancer and, in particular, to therapies that are particularly suited to tumor cells resistant to other types of therapies such as radiation, chemotherapy, or combinations of both approaches. The invention provides methods for identifying and implementing strategies to inhibit a transcription factor which, in combination with other factors, renders the cells resistant and inhibits apopotosis of the cells. The invention provides an inhibitory ATF2 N-terminal fragment, specifically a fragment corresponding to amino acid residues 50-100 of ATF2 (termed peptide II). The invention provides methods for inhibiting tumor cell growth with such peptides.

REFERENCES:
patent: 5736381 (1998-04-01), Davis et al.
patent: 6335178 (2002-01-01), Weiner et al.
patent: 6579856 (2003-06-01), Mercola
Choi et al (J. Biol. Chem. Jul. 4, 1997; 272 (27): 16934-16939).
Verma et al. (Nature 1997, 389: 239-242).
Amalfitano et al. (Current Gene Therapy 2002, 2: 111-133).
Pandha et al. (Current Opinion in Investigational Drugs 2000; 1 (1): 122-134).
Ferrari et al. (Clin. Exp. Immunol. 2003; 132: 1-8).
Zeimet et al. (Lancet. Jul. 2003; 4: 415-422).
Riva (Anticancer Res. 2000; 20: 4463-4471).
Gura (Science. 1997; 278: 1041-1042).
Dennis (Nature. Aug. 7, 2006; 442: 739-741).
Saijo et al. (Cancer Sci. Oct. 2004; 95 (10): 772-776).
Kelland (Eur. J. Cancer. Apr. 2004; 40 (6): 827-836).
Bergers et al. (Current Opinion in Genetics and Development. 2000; 10: 120-127).
Ahmed et al. (J. Immunol. 2006; 177: 315-321).
Crawford et al. (Annu. Rev. Genomics Hum. Genet. 2005; 6: 287-312).
GenBank™ Accession No. AAH26175 (Version AAH26175.1; GI:20072897).
GenBank™ Accession No. BC026175 (Version BC026175.1; GI:20072896).
Bailey et al. (J. Mol. Endocrinol. Feb. 2005; 34 (1): 19-35).
Jobling et al. (Plasmid. 1997; 38: 158-173).
Nilsson et al. (Nucleic Acid Res. 1985; 13 (4): 1151-1162).
Livingstone et al. (EMBO J. 1995; 14 (8): 1785-1797).
Abdel-Hafiz et al. (Mol. Endocrinol. Dec. 1992; 6 (12): 2079-2089).
Duyndam et al. (Oncogene. 1999; 18: 2311-2321).
Bhoumik et al. (Cancer Res. Nov. 15, 2004; 64: 8222-8230).
Bhoumik et al. (Proc. Natl. Acad. Sci USA. Mar. 23, 2004; 101 (12): 4222-4227).
Mi et al. (Mol. Ther. Oct. 2000; 2 (4): 339-347).
Cho et al., TIP49b, a Regulator of Activating Transcription Factor 2 Response to Stress and DNA damage. Mol. Cell. Biol. 2001. 21: 8398-8413.
Buschmann et al., Amino-terminal-derived JNK Fragment Alters Expression and Activity of c-Jun, ATF2, and p56 and Increases H202-Induced Cell Death, J. Biol. Chem. 2000; 278: 16590-96.
Duyndam MCA, et al. Oncogene. 1999; 18: 2311-21.
Gura T. Science. 1997; 278: 1041-42.
van Dam H, et al. EMBO J. Apr. 18, 1995; 14 (8): 1798-811.
Anindita Bhoumik et al., “An ATF2-Derived Peptide Sensitizes Melanomas to Apoptosis and Inhibits Their Growth and Metastasis,” Sep. 2002, vol. 110, No. 5, pp. 643-650.
Anindita Bhoumik et al., “Transcriptional Switch by Activating Transcription Factor 2-Derived Peptide Sensitizes Melanoma Cells to Apoptosis and Inhibits Their Tumorigenicity,” Mar. 23, 2004, vol. 101, No. 12, pp. 4222-4227.
Fritz et al., Journal of Biological Chemistry 1997; 272: 30637-30644 (abstract only).
Bhourmik et al., Clin. Cancer Res. 2001; 7(2):331-42.
Ivanov, V.N., and Ronai, Z., Oncogene 2000; 19: 3003-3012.
Ivanov, V.N. et al., Oncogene 2000; 19: 933-942.
Yang, Y.-M et al., Oncogene, 12 :2223-2233, 1996.
Ronai, Z. et al, Oncogene 1998; 16: 523-531.
Ivanov, V.N. et al., J. Biol. Chem. 1999; 274:14079-14089.
Gupta, S. et al., Science 1995; 267: 389-393.
Fuchs, S.Y. and Ronai, Z., Mol. Cell Biol. 1999; 19: 3289-3298.
Georgopoulos, K. et al., Mol. Cell. Biol.1992; 12: 747-757.
Huguier S. et al., Mol. Cell Biol. 1988; 18:7020-7029.

Affiliated with

Also associated with

Rating

Inhibition of ATF2 activity to treat cancer does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Inhibition of ATF2 activity to treat cancer, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibition of ATF2 activity to treat cancer will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2653883